| A Comparative Look at the Safety Profiles of Intravenous Iron Products Used in the Hemodialysis Population (February). | |
| | |
MedLine Citation:
|
PMID: 21304025 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
OBJECTIVE: To review clinical trials conducted in hemodialysis patients of the 4 intravenous iron products available in the US in an attempt to discern strengths and inferiorities between products and evaluate current safety data that can be used to assist the clinician in selecting the most appropriate agent. DATA SOURCES: Literature was accessed through PubMed (January 2000-October 2010). In some cases, reference citations from selected review articles were evaluated as well. STUDY SELECTION AND DATA EXTRACTION: Clinical trials published in the English language were selected using the search terms iron dextran, iron sucrose, sodium ferric gluconate, and ferumoxytol. Studies were further pared down to include only those enrolling hemodialysis patients. DATA SYNTHESIS: There are currently 4 intravenous iron formulations in the US used to treat iron-deficiency anemia in hemodialysis patients. Ferumoxytol has not yet been directly compared to the other 3 agents. Eight studies have been conducted in hemodialysis patients directly comparing iron dextran, iron sucrose, and/or sodium ferric gluconate. These studies were further categorized for evaluation based on iron products compared. Four studies directly compared iron dextran to iron sucrose, 1 study compared iron dextran to sodium ferric gluconate, 1 study compared iron sucrose to sodium ferric gluconate, and 2 studies compared all 3 agents. Of the 3 agents, iron dextran appears to have the least favorable safety profile, while iron sucrose appears most favorable. CONCLUSIONS: The newest intravenous iron product, ferumoxytol, has not been directly compared to the other 3 agents. Large well-controlled studies of these products specifically in the hemodialysis population would further help clinicians determine appropriate therapy. Iron sucrose appears to offer the most favorable safety profile when compared to iron dextran and sodium ferric gluconate in treating hemodialysis patients. Oxidative stress and hypersensitivity reactions are common problems encountered when administering intravenous iron. |
| | |
Authors:
|
Elena Coppol; Jamie Shelly; Stephanie Cheng; Yaman Kaakeh; Brian Shepler |
Related Documents
:
|
10807885 - Cough threshold in reflux oesophagitis: influence of acid and of laryngeal and oesophag... 15218995 - Increased gastro-oesophageal reflux disease in patients with severe copd. 2929555 - Is long-term esophageal ph monitoring of clinical value? 11448445 - Pharyngeal ph measurements in patients with respiratory symptoms before and during prot... 19890575 - Characteristics, and disease control and complications of hypertensive patients in prim... 3706155 - Risk of myocardium adjacent to infarcted myocardium: electrocardiographic, metabolic an... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-2-8 |
Journal Detail:
|
Title: The Annals of pharmacotherapy Volume: - ISSN: 1542-6270 ISO Abbreviation: - Publication Date: 2011 Feb |
Date Detail:
|
Created Date: 2011-2-9 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9203131 Medline TA: Ann Pharmacother Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
College of Pharmacy, Purdue University, West Lafayette, IN. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Impact of a Pharmacist-Directed Anticoagulation Service on the Quality and Safety of Heparin-Induced...
Next Document: Regional, Geographic, and Ethnic Differences in Medication Adherence Among Adults with Type 2 Diabet...